The FLT3 inhibitor gilteritinib did also not improve OS when added to azacitidine in older unfit patients with AML with mutated FLT3 (LACEWING trial), despite a significantly higher complete remission rate of 58.1% versus 26.5% for the azacitidine alone arm (P < 0.001) [10]. The gene discussed is FLT3; the disease is acute myeloid leukemia.